Financials · MD
For the twelve months ended Sep 30, 2026, Pediatrix Medical Group Inc. reported $1.96B of revenue and $150.09M of net income.
MD revenue was $501.37M in fiscal Q3 2026 (ended Sep 30, 2026), up 1.7% from a year earlier and up 2.8% from the prior quarter. For the full fiscal 2025 it was $1.91B, down 4.9% from fiscal 2024. Compound annual growth was +2.0% over 5 years and -3.7% over 10 years. It rose in 7 of the last 10 fiscal years.
MD net income was $46.99M in fiscal Q3 2026 (ended Sep 30, 2026), down 34.5% from a year earlier and up 17.9% from the prior quarter. For the full fiscal 2025 it was $165.39M, compared with -$99.07M in fiscal 2024. Compound annual growth was -6.9% over 10 years.
MD diluted EPS was $0.59 in fiscal Q3 2026 (ended Sep 30, 2026), down 29.8% from a year earlier and up 20.4% from the prior quarter. For the full fiscal 2025 it was $1.94, compared with -$1.19 in fiscal 2024. Compound annual growth was -5.9% over 10 years.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.91B | $2.01B | $1.99B | $1.97B | $1.91B | $1.73B | $1.78B | $1.72B | $3.25B | $3.18B |
| Selling, general and admin | $240.79M | $238.44M | $227.54M | $231.40M | $263.36M | $248.95M | $244.51M | $232.22M | $385.86M | $372.57M |
| Operating income | $208.81M | -$68.71M | $7.32M | $172.69M | $202.92M | $98.13M | $171.76M | $248.39M | $454.89M | $571.69M |
| Interest expense | $35.97M | $40.74M | $42.08M | $39.70M | $68.72M | $110.48M | $118.93M | $92.94M | $74.56M | $63.09M |
| Pre-tax income | $216.43M | -$101.34M | -$48.36M | $81.37M | $135.23M | $7.15M | $58.78M | $166.21M | $385.67M | $513.80M |
| Income tax | $51.04M | -$2.27M | $12.05M | $18.81M | $27.24M | $16.73M | $16.58M | $44.69M | $80.23M | $189.20M |
| Net income | $165.39M | -$99.07M | -$60.41M | $66.33M | $130.96M | -$796.49M | -$1.50B | $268.63M | $320.37M | $324.91M |
| EPS, basic | $1.97 | -$1.19 | -$0.73 | $0.79 | $1.54 | -$9.55 | -$17.94 | $2.95 | $3.47 | $3.52 |
| EPS, diluted | $1.94 | -$1.19 | -$0.73 | $0.79 | $1.53 | -$9.55 | -$17.83 | $2.93 | $3.45 | $3.49 |
| Diluted shares | 85.3M | 83.3M | 82.2M | 84.1M | 85.8M | 83.4M | 84.0M | 91.6M | 93.0M | 93.1M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $375.24M | $229.94M | $73.26M | $9.82M | $387.39M | $1.12B | $107.87M | $40.77M | $40.45M | $55.70M |
| Short-term investments | - | - | - | - | - | - | $0 | $21.92M | - | - |
| Receivables | $229.66M | $259.99M | $272.31M | $296.79M | $301.77M | $241.93M | $434.27M | $506.72M | $504.00M | $495.28M |
| Current assets | $763.51M | $639.61M | $483.45M | $427.99M | $840.56M | $1.55B | $731.51M | $659.98M | $627.24M | $587.13M |
| Goodwill | $1.26B | $1.24B | $1.38B | $1.53B | $1.51B | $1.48B | $1.48B | $4.06B | $4.28B | $3.85B |
| Total assets | $2.25B | $2.15B | $2.22B | $2.35B | $2.72B | $3.35B | $4.15B | $5.94B | $5.87B | $5.34B |
| Current liabilities | $458.91M | $434.11M | $388.95M | $426.98M | $427.37M | $444.33M | $541.82M | $502.76M | $531.42M | $448.95M |
| Short-term debt | - | - | - | - | - | - | - | - | - | $20.00M |
| Long-term debt | $570.53M | $597.12M | $618.42M | $632.38M | - | - | - | - | - | $1.68B |
| Total debt | $570.53M | $597.12M | $618.42M | $632.38M | $989.70M | $1.70B | $1.70B | $1.97B | $1.85B | $1.70B |
| Total liabilities | $1.38B | $1.39B | $1.37B | $1.46B | $1.83B | $2.60B | $2.65B | $2.85B | $2.80B | $2.58B |
| Shareholders' equity | $865.85M | $764.94M | $849.06M | $891.63M | $896.69M | $747.72M | $1.50B | $3.09B | $3.07B | $2.76B |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $271.09M | $206.57M | $137.32M | $166.94M | $76.74M | $204.62M | $357.71M | $313.71M | $511.38M | $443.78M |
| Investing cash flow | -$18.30M | -$35.41M | -$48.18M | -$56.95M | -$53.07M | $815.51M | $102.45M | -$142.77M | -$576.61M | -$821.22M |
| Financing cash flow | -$107.49M | -$14.48M | -$25.71M | -$487.55M | -$760.12M | -$4.16M | -$393.07M | -$170.61M | $89.74M | $381.56M |
| Share repurchases | $86.68M | $1.70M | $919.0K | $88.51M | $4.72M | $8.49M | $145.28M | $302.16M | $70.19M | $61.83M |
| Stock-based compensation | $18.05M | $11.87M | $12.32M | $16.13M | $18.97M | $39.04M | $33.41M | $36.59M | $28.78M | $34.00M |
| Depreciation and amortization | $21.83M | $32.23M | $36.17M | $35.64M | $32.15M | $28.44M | $25.93M | $24.36M | $78.86M | $89.26M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -4.9% | 0.9% | 1.1% | 3.2% | 10.2% | -2.6% | 3.3% | -47.0% | 2.2% | 14.5% |
| Net income growth, YoY | - | - | - | -49.3% | - | - | - | -16.2% | -1.4% | -3.4% |
| EPS growth, YoY | - | - | - | -48.4% | - | - | - | -15.1% | -1.1% | -2.5% |
| Operating margin | 10.9% | -3.4% | 0.4% | 8.8% | 10.6% | 5.7% | 9.7% | 14.4% | 14.0% | 18.0% |
| Net margin | 8.6% | -4.9% | -3.0% | 3.4% | 6.9% | -45.9% | -84.2% | 15.6% | 9.8% | 10.2% |
| Return on equity | 19.1% | -13.0% | -7.1% | 7.4% | 14.6% | -106.5% | -99.9% | 8.7% | 10.4% | 11.8% |
| Return on assets | 7.4% | -4.6% | -2.7% | 2.8% | 4.8% | -23.8% | -36.1% | 4.5% | 5.5% | 6.1% |
| Current ratio | 1.66 | 1.47 | 1.24 | 1.00 | 1.97 | 3.49 | 1.35 | 1.31 | 1.18 | 1.31 |
| Debt to equity | 0.66 | 0.78 | 0.73 | 0.71 | 1.10 | 2.27 | 1.13 | 0.64 | 0.60 | 0.62 |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $501.37M | $487.78M | $476.20M | $493.77M | $492.88M | $468.84M | $458.36M | $502.36M | $511.16M | $504.30M | $495.10M | $496.44M |
| Selling, general and admin | $62.70M | $61.29M | $60.27M | $65.68M | $60.79M | $55.71M | $58.60M | $63.55M | $58.12M | $56.56M | $60.20M | $53.06M |
| Operating income | $65.21M | $56.92M | $41.66M | $48.79M | $68.05M | $59.87M | $32.10M | $39.29M | $33.83M | -$157.72M | $15.89M | -$111.49M |
| Interest expense | $8.13M | $8.17M | $8.27M | $8.74M | $8.94M | $9.13M | $9.15M | $9.71M | $10.13M | $10.31M | $10.60M | $10.08M |
| Pre-tax income | $64.99M | $54.00M | $38.84M | $45.59M | $87.78M | $54.97M | $28.09M | $33.33M | $25.23M | -$167.73M | $7.82M | -$138.85M |
| Income tax | $18.00M | $14.16M | $9.27M | $11.91M | $16.07M | $15.71M | $7.35M | $2.85M | $5.79M | -$14.70M | $3.79M | -$14.56M |
| Net income | $46.99M | $39.84M | $29.57M | $33.68M | $71.71M | $39.26M | $20.74M | $30.48M | $19.44M | -$153.03M | $4.04M | -$124.29M |
| EPS, basic | $0.61 | $0.50 | $0.37 | $0.41 | $0.85 | $0.46 | $0.25 | $0.37 | $0.23 | -$1.84 | $0.05 | -$1.50 |
| EPS, diluted | $0.59 | $0.49 | $0.36 | $0.40 | $0.84 | $0.46 | $0.24 | $0.37 | $0.23 | -$1.84 | $0.05 | -$1.50 |
| Diluted shares | 79.7M | 81.4M | 83.1M | - | 85.6M | 85.5M | 85.4M | - | 84.5M | 83.3M | 83.3M | - |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $311.92M | $288.88M | $205.78M | $375.24M | $340.06M | $224.73M | $98.98M | $229.94M | $103.83M | $19.40M | $8.00M | $73.26M |
| Receivables | $231.82M | $227.60M | $224.80M | $229.66M | $231.12M | $238.99M | $242.53M | $259.99M | $286.90M | $274.16M | $283.75M | $272.31M |
| Current assets | $684.08M | $660.14M | $587.03M | $763.51M | $717.20M | $613.05M | $491.67M | $639.61M | $528.22M | $429.21M | $426.52M | $483.45M |
| Goodwill | $1.27B | $1.27B | $1.27B | $1.26B | $1.26B | $1.24B | $1.24B | $1.24B | $1.24B | $1.24B | $1.39B | $1.38B |
| Total assets | $2.14B | $2.13B | $2.07B | $2.25B | $2.20B | $2.10B | $1.99B | $2.15B | $2.08B | $2.00B | $2.17B | $2.22B |
| Current liabilities | $535.73M | $501.58M | $442.64M | $458.91M | $392.55M | $341.04M | $271.05M | $434.11M | $373.08M | $310.16M | $247.28M | $388.95M |
| Long-term debt | $397.77M | $398.06M | $398.35M | $570.53M | $577.17M | $583.86M | $590.48M | $597.12M | - | - | - | $618.42M |
| Total debt | $397.77M | $398.06M | $398.35M | $570.53M | $577.17M | $583.86M | $590.48M | $597.12M | - | - | - | $618.42M |
| Total liabilities | $1.29B | $1.25B | $1.19B | $1.38B | $1.31B | $1.27B | $1.20B | $1.39B | $1.34B | $1.29B | $1.31B | $1.37B |
| Shareholders' equity | $849.62M | $880.98M | $878.58M | $865.85M | $890.67M | $833.75M | $789.19M | $764.94M | $732.49M | $706.46M | $856.20M | $849.06M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $117.31M | $125.32M | -$129.85M | $114.10M | $137.28M | $137.17M | -$117.46M | $133.01M | $91.84M | $106.95M | -$125.23M | $69.25M |
| Investing cash flow | -$4.64M | $6.02M | -$11.98M | -$10.28M | $6.60M | -$7.15M | -$7.46M | -$1.94M | -$4.34M | -$12.89M | -$16.24M | -$12.42M |
| Financing cash flow | -$89.63M | -$48.24M | -$27.64M | -$68.64M | -$28.56M | -$4.26M | -$6.04M | -$4.96M | -$3.07M | -$82.66M | $76.20M | -$4.75M |
| Share repurchases | $83.04M | $42.74M | $21.45M | $64.04M | $20.87M | $209.0K | $1.57M | $643.0K | $162.0K | $11.0K | $887.0K | $0 |
| Stock-based compensation | $6.20M | $5.08M | $4.66M | $5.34M | $5.15M | $3.91M | $3.64M | $2.74M | $4.11M | $1.95M | $3.07M | $3.02M |
| Depreciation and amortization | $6.24M | $5.78M | $6.12M | $5.63M | $5.55M | $5.31M | $5.33M | $6.87M | $6.25M | $8.79M | $10.31M | $9.06M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 1.7% | 4.0% | 3.9% | -1.7% | -3.6% | -7.0% | -7.4% | 1.2% | 0.9% | 0.7% | 0.8% | -3.4% |
| Net income growth, YoY | -34.5% | 1.5% | 42.6% | 10.5% | 268.8% | - | 413.9% | - | -9.1% | - | -71.6% | - |
| EPS growth, YoY | -29.8% | 6.5% | 50.0% | 8.1% | 265.2% | - | 380.0% | - | -11.5% | - | -70.6% | - |
| Operating margin | 13.0% | 11.7% | 8.7% | 9.9% | 13.8% | 12.8% | 7.0% | 7.8% | 6.6% | -31.3% | 3.2% | -22.5% |
| Net margin | 9.4% | 8.2% | 6.2% | 6.8% | 14.5% | 8.4% | 4.5% | 6.1% | 3.8% | -30.3% | 0.8% | -25.0% |
| Current ratio | 1.28 | 1.32 | 1.33 | 1.66 | 1.83 | 1.80 | 1.81 | 1.47 | 1.42 | 1.38 | 1.72 | 1.24 |
| Debt to equity | 0.47 | 0.45 | 0.45 | 0.66 | 0.65 | 0.70 | 0.75 | 0.78 | - | - | - | 0.73 |
Source: XBRL data Pediatrix Medical Group Inc. files with the SEC, latest filing dated Oct 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 2-for-1, first reported Feb 12, 2014.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MD | $1.96B | +1.9% | $150.09M | 7.7% | $2.44B |
| HCA | $78.70B | +5.8% | $6.78B | 8.6% | $103.40B |
| THC | $22.15B | +6.2% | $2.90B | 13.1% | $22.55B |
| EHC | $6.34B | +9.4% | $644.40M | 10.2% | $13.50B |
| UHS | $18.35B | +8.0% | $1.46B | 8.0% | $11.52B |
| ENSG | $5.67B | +17.5% | $399.12M | 7.0% | $10.56B |
| PACS | $5.71B | +11.0% | $277.58M | 4.9% | $7.87B |
| NHC | $1.58B | +5.6% | $115.13M | 7.3% | $3.27B |
| SGRY | $3.37B | +4.0% | -$88.60M | -2.6% | $3.04B |